Oncobiologics, Inc. (NASDAQ:ONS) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03
|
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
On November 23, 2016, the Board of Directors of Oncobiologics,
Inc. (the Company) adopted an amendment (the Amendment) to the
Companys Amended and Restated Bylaws (the Bylaws), effective
immediately, to add a new Article XIV, Section 47 to the
Bylaws.The new provision provides that, unless the Company
consents in writing to the selection of an alternative forum, the
Court of Chancery of the State of Delaware shall be the sole and
exclusive forum for (a) any derivative action or proceeding
brought on behalf of the Company, (b) any action asserting a
claim of breach of a fiduciary duty owed by any director, officer
or other employee of the Company to the Company or the Companys
stockholders, (c) any action asserting a claim arising to any
provision of the Delaware General Corporation Law, the
certificate of incorporation or the bylaws of the Company, or (d)
any action asserting a claim governed by the internal affairs
doctrine.
The foregoing summary of the Amendment is qualified in its
entirety by reference to the complete text of the Amendment, a
copy of which is attached to this Current Report on Form 8-K as
Exhibit 3.1.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description | |
| 3.1 |
Amendment to the Oncobiologics, Inc. Amended and Restated the Bylaws |
About Oncobiologics, Inc. (NASDAQ:ONS)
Oncobiologics, Inc. is a United States-based clinical stage-biopharmaceutical company. The Company focuses on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It focuses on monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Its pipeline includes ONS-3010 (Adalimumab), ONS-1045 (Bevacizumab), ONS-1050 (Trastuzumab) and ONS-4010 (Denosumab). Its BioSymphony platform addresses biologics industry by developing mAb biosimilars on an accelerated timeline. It utilizes mini bioreactors to assess the screened clones and media components to determine, which clone and process will produce a biosimilar candidate with match to the reference product. It uses techniques to screen and evaluate various formulation variations to identify the stable formulation. It utilizes analytical techniques and instruments to enable the users to interpret the chemical and structural similarity between its biosimilar candidate and the reference product. Oncobiologics, Inc. (NASDAQ:ONS) Recent Trading Information
Oncobiologics, Inc. (NASDAQ:ONS) closed its last trading session down -0.03 at 3.71 with 661 shares trading hands.
